In this module, Komal Jhaveri, MD, FACP, reviews the role of TROP-2 directed antibody drug conjugates in the therapeutic landscape for patients with HER2-negative advanced breast cancer, including HER2-low disease, and the clinical implications for treatment selection.
- Provider:Clinical Care Options
- Activity Link: https://clinicaloptions.com/CE-CME/oncology/trop2-targeted-therapy-module-1/18634-27331
- Start Date: 2024-02-22 06:00:00
- End Date: 2024-02-22 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.75 hours
- Commercial Support: Source: AstraZeneca (Any division) - Amount: 40000.0 - Is Kind Support: False Source: Daiichi Sankyo, Inc. - Amount: 40000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest